A detailed history of Crewe Advisors LLC transactions in Biomarin Pharmaceutical Inc stock. As of the latest transaction made, Crewe Advisors LLC holds 250 shares of BMRN stock, worth $16,492. This represents 0.0% of its overall portfolio holdings.

Number of Shares
250
Previous 250 -0.0%
Holding current value
$16,492
Previous $20,000 15.0%
% of portfolio
0.0%
Previous 0.0%

Shares

6 transactions
Quarter Operation Price Per share shares change shares Held SEC Form
Q1 2024

May 13, 2024

BUY
$83.81 - $99.0 $20,952 - $24,750
250 New
250 $21,000
Q4 2022

Feb 07, 2023

SELL
$80.93 - $108.63 $5,988 - $8,038
-74 Reduced 37.0%
126 $13,000
Q3 2022

Nov 14, 2022

BUY
$82.16 - $96.94 $2,464 - $2,908
30 Added 17.65%
200 $17,000
Q2 2022

Aug 02, 2022

BUY
$71.48 - $86.85 $12,151 - $14,764
170 New
170 $14,000
Q4 2020

Jan 27, 2021

SELL
$72.61 - $90.2 $1,089 - $1,353
-15 Closed
0 $0
Q3 2020

Oct 13, 2020

BUY
$71.87 - $131.03 $1,078 - $1,965
15 New
15 $1,000

Others Institutions Holding BMRN

About BIOMARIN PHARMACEUTICAL INC


  • Ticker BMRN
  • Exchange NASDAQ
  • Sector Healthcare
  • Industry Biotechnology
  • Shares Outstandng 185,824,000
  • Market Cap $12.3B
  • Description
  • BioMarin Pharmaceutical Inc. develops and commercializes therapies for people with serious and life-threatening rare diseases and medical conditions. Its commercial products include Vimizim, an enzyme replacement therapy for the treatment of mucopolysaccharidosis (MPS) IV type A, a lysosomal storage disorder; Naglazyme, a recombinant form of N-a...
More about BMRN
Track This Portfolio

Track Crewe Advisors LLC Portfolio

Follow Crewe Advisors LLC and customize your updates to receive the information that matters most to you.

Portfolio Update

Get notified when there are updates to the investment portfolio of Crewe Advisors LLC, based on Form 13F filings with the SEC.

News

Stay updated on Crewe Advisors LLC with notifications on news.